Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray

Stopped early · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Motion Sickness

In brief

Part 1, the pharmacokinetic (PK) phase, will expand upon the pilot study conducted at Naval Medical Research Laboratory (NAMRL) and has the goal of determining bioavailability and time to Cmax in a larger representative sample. Part 2, the efficacy phase, is to determine the efficacy of the aqueous spray solution via exposure to a nausea-inducing stimulus.

Key facts

Study ID
NCT02155309
Run by
Repurposed Therapeutics, Inc.
People needed
63
Starts
2014-06-01
Expected to finish
2016-03-01
Last updated by the study team
2018-01-17

Who can join

Age: 18 and older, up to 59. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.